IMNM Immunome Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and commercialization of first- and best-in-class targeted oncology therapies with focus on antibody-drug conjugates (ADCs) and radioligand therapies (RLTs)
• • New emphasis on varegacestat for desmoid tumors with positive Phase 3 results and planned NDA submission Q2 2026
• • Strategic shift to advancing innovative pipeline including IM-1021 (ROR1 ADC in Phase 1) and IM-3050 (FAP-targeted RLT with IND clearance in April 2025)
• • Pipeline breadth: 3 clinical and 3 preclinical assets; positive Phase 3 topline for varegacestat showing 84% PFS risk reduction (HR=0.16, p<0.0001)
• • Noteworthy: Acquisition of varegacestat from Ayala Pharmaceuticals in March 2024 and fastest pivotal study hazard ratio reported in desmoid tumor population

Risk Factors

• • Cybersecurity risk with potential regulatory fines, litigation, operational disruption, and reputational harm from IT system compromises
• • Key-person dependency on three senior IT officers managing cybersecurity, including Head of IT and Senior Director with 30+ years biotech experience
• • Board audit committee oversight of cybersecurity risk management and incident reporting, with escalation protocols for material cyber threats

Management Discussion & Analysis

• • Collaboration revenue $6.9M, down $2.1M YoY from $9.0M, ceasing after July 2025 termination
• • Operating margin improvement: operating loss $224.1M vs $305.8M, R&D expenses up to $177.3M vs $129.5M, G&A $43.8M vs $33.0M
• • Best segment: Varegacestat R&D $52.4M, up $24.4M YoY; Worst segment: IM-1021 R&D $11.0M, down $13.1M YoY
• • Cash flow 2025: Operating cash use $190.9M vs $110.8M; Financing inflows $640.4M (public offerings and ATM); Capex $9.7M and IPR&D purchase $6.2M
• • Outlook: NDA submission for varegacestat Q2 2026; Increased R&D and G&A expected for clinical advancement and commercialization; Additional financing likely needed beyond 12 months

What are the latest IMNM SEC filings in 2026?

Immunome Inc. (IMNM) has filed a 10-K annual report on March 3, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on June 12, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did IMNM file its most recent 10-K annual report?

Immunome Inc. (IMNM) filed its most recent 10-K annual report on March 3, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view IMNM 10-Q quarterly reports?

Immunome Inc. (IMNM)'s most recent 10-Q quarterly report was filed on May 12, 2026. SignalX displays every IMNM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has IMNM filed recently?

Immunome Inc. (IMNM)'s most recent 8-K was filed on June 12, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find IMNM insider trading activity (Form 4)?

SignalX aggregates every IMNM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does IMNM file with the SEC?

Immunome Inc. (IMNM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IMNM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Immunome Inc. (IMNM).

What is IMNM's SEC CIK number?

Immunome Inc. (IMNM)'s SEC CIK (Central Index Key) number is 1472012. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1472012 to look up all IMNM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find IMNM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Immunome Inc. (IMNM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.